Cyclin-dependent kinase-9: an RNAPII kinase at the nexus of cardiac growth and death cascades
- PMID: 15514168
- DOI: 10.1161/01.RES.0000146675.88354.04
Cyclin-dependent kinase-9: an RNAPII kinase at the nexus of cardiac growth and death cascades
Abstract
Over the past decade and a half, the paradigm has emerged of cardiac hypertrophy and ensuing heart failure as fundamentally a problem in signal transduction, impinging on the altered expression or function of gene-specific transcription factors and their partners, which then execute the hypertrophic phenotype. Strikingly, RNA polymerase II (RNAPII) is itself a substrate for two protein kinases-the cyclin-dependent kinases Cdk7 and Cdk9--that are activated by hypertrophic cues. Phosphorylation of RNAPII in the carboxyl terminal domain (CTD) of its largest subunit controls a number of critical steps subsequent to transcription initiation, among them enabling RNAPII to overcome its stalling in the promoter-proximal region and to engage in efficient transcription elongation. Here, we summarize our current understanding of the RNAPII-directed protein kinases in cardiac hypertrophy. Cdk9 activation is essential in tissue culture for myocyte enlargement and sufficient in transgenic mice for hypertrophy to occur and yet is unrelated to the "fetal" gene program that is typical of pathophysiological heart growth. Although this trophic effect of Cdk9 appears benign superficially, pathophysiological levels of Cdk9 activity render myocardium remarkably susceptible to apoptotic stress. Cdk9 interacts adversely with Gq-dependent pathways for hypertrophy, impairing the expression of numerous genes for mitochondrial proteins, and, in particular, suppressing master regulators of mitochondrial biogenesis and function, perioxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1), and nuclear respiratory factor-1 (NRF-1). Given the dual transcriptional roles of Cdk9 in hypertrophic growth and mitochondrial dysfunction, we suggest the potential usefulness of Cdk9 as a target in heart failure drug discovery.
Similar articles
-
Pharmacological targeting of CDK9 in cardiac hypertrophy.Med Res Rev. 2010 Jul;30(4):646-66. doi: 10.1002/med.20172. Med Res Rev. 2010. PMID: 19757441 Review.
-
Activation of cardiac Cdk9 represses PGC-1 and confers a predisposition to heart failure.EMBO J. 2004 Sep 1;23(17):3559-69. doi: 10.1038/sj.emboj.7600351. Epub 2004 Aug 5. EMBO J. 2004. PMID: 15297879 Free PMC article.
-
Phosphorylation of RNA polymerase II in cardiac hypertrophy: cell enlargement signals converge on cyclin T/Cdk9.Recent Prog Horm Res. 2004;59:125-39. doi: 10.1210/rp.59.1.125. Recent Prog Horm Res. 2004. PMID: 14749500 Review.
-
Cyclins that don't cycle--cyclin T/cyclin-dependent kinase-9 determines cardiac muscle cell size.Cell Cycle. 2003 Mar-Apr;2(2):99-104. Cell Cycle. 2003. PMID: 12695656 Review.
-
Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy.Nat Med. 2002 Nov;8(11):1310-7. doi: 10.1038/nm778. Epub 2002 Sep 30. Nat Med. 2002. PMID: 12368904
Cited by
-
PGC-1α Is a Master Regulator of Mitochondrial Lifecycle and ROS Stress Response.Antioxidants (Basel). 2023 May 10;12(5):1075. doi: 10.3390/antiox12051075. Antioxidants (Basel). 2023. PMID: 37237941 Free PMC article. Review.
-
Therapeutic Hypothermia Inhibits Hypoxia-Induced Cardiomyocyte Apoptosis Via the MiR-483-3p/Cdk9 Axis.J Am Heart Assoc. 2023 Feb 21;12(4):e026160. doi: 10.1161/JAHA.122.026160. Epub 2023 Feb 15. J Am Heart Assoc. 2023. PMID: 36789845 Free PMC article.
-
Pyrazole-Curcumin Suppresses Cardiomyocyte Hypertrophy by Disrupting the CDK9/CyclinT1 Complex.Pharmaceutics. 2022 Jun 15;14(6):1269. doi: 10.3390/pharmaceutics14061269. Pharmaceutics. 2022. PMID: 35745840 Free PMC article.
-
P-TEFb as A Promising Therapeutic Target.Molecules. 2020 Feb 14;25(4):838. doi: 10.3390/molecules25040838. Molecules. 2020. PMID: 32075058 Free PMC article. Review.
-
Associations of genetic variants of endothelin with cardiovascular complications in patients with renal failure.BMC Nephrol. 2017 Sep 7;18(1):291. doi: 10.1186/s12882-017-0707-2. BMC Nephrol. 2017. PMID: 28882114 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous